chrisvoncsefalvay/vaers-outcomes huggingface dataset:
soreness, redness, and itchiness at injection site; soreness, redness, and itchiness at injection site; soreness, redness, and itchiness at injection site; This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION SITE PRURITUS (soreness, redness, and itchiness at injection site), VACCINATION SITE PAIN (soreness, redness, and itchiness at injection site) and VACCINATION SITE ERYTHEMA (soreness, redness, and itchiness at injection site) in an 81-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 004C21A and 048A21A) for COVID-19 vaccination.     No medical history was provided by the reporter.  Concomitant products included METOPROLOL, LISINOPRIL, ATORVASTATIN CALCIUM, EZETIMIBE (STATIN EZ), METFORMIN and ERGOCALCIFEROL, RETINOL PALMITATE (VITAMINS A & D) for an unknown indication.   On 30-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 29-Apr-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 30-Apr-2021, the patient experienced VACCINATION SITE PRURITUS (soreness, redness, and itchiness at injection site), VACCINATION SITE PAIN (soreness, redness, and itchiness at injection site) and VACCINATION SITE ERYTHEMA (soreness, redness, and itchiness at injection site). At the time of the report, VACCINATION SITE PRURITUS (soreness, redness, and itchiness at injection site), VACCINATION SITE PAIN (soreness, redness, and itchiness at injection site) and VACCINATION SITE ERYTHEMA (soreness, redness, and itchiness at injection site) outcome was unknown.            The patient was treated with Neosporin.  The action taken with  mRNA-1273 (Moderna COVID-19 Vaccine) was not applicable.
Administered Pfizer 6mos-4yo monovalent dose as third dose in series when Pfizer 6mos-4yo bivalent dose indicated.
5/27/22 7 PM - Bad headache and  extremely loud ringing in ears 9 PM -  took 250mg Motrin; did not seem to alleviate either symptom; symptoms kept me awake most of the night 5/28/22 - both symptoms have mostly subsided by evening
Pt had covid vacc on 3/25/21 first dose- 4/6/21 Someone called and said she had what he thought was lymph node swelling in neck that started that day. I told him there was a chance it was the vacc but could also be signs of infection. moderna info says about 10% chance within 7 days. 4/7/21 Someone came in and said the mild swelling was back down. I recommended that they do the V safe program
High fever, nausea, headache, body aches, heat near injection site, swelling of injection arm.
Guaiac positive stool with few flecks of blood; stool green, frothy in texture on the day vaccine administration.
This spontaneous report was received from a nurse referring to a patient of unknown age and gender. The patient's pertinent medical history, drug reactions/allergies, concurrent conditions and concomitant medications were not reported. In 2017 (reported as "on or after 05-JUL-2017"), the patient was vaccinated with an improperly stored dose of RECOMBIVAX HB lot # M040423 with expiration date 03-JUL-2019; an improperly stored dose of ROTATEQ per oral, lot # M044396 with expiration date 19-JUN-2018; or an improperly stored dose of VAQTA lot # N005274 with expiration date 03-APR-2018, for prophylaxis (dose and route of administration were not reported). It was stated that the vaccine was exposed to a temperature of 32 to 35 Fahrenheit degrees with a time frame of 1 hour. No previous temperature excursion was reported. The reporter did not know which vaccine was administered to the patient. This is one of several reports from the same reporter.; Sender's Comments:  US-009507513-1710USA015406: US-009507513-1711USA008229: US-009507513-1711USA008230: US-009507513-1711USA008231: US-009507513-1711USA008232: US-009507513-1711USA008233:
Mom states son ran high fever (102 to 103) starting "about an hour after the shots" for most of weekend. Developed severe headache and "walked into a wall." Child seen in ER. All lab work and lumbar puncture were unremarkable. Mom kept son home from school today. He is fever free and feeling better.
Fever 102 degrees on 10-29-10. Reported redness and swelling to her entire left upper arm to her elbow. Parent took child to Dr who placed child on antibiotic. The ABT given her was Cephalexin.
No additional AE; Temperature excursion involving administered PROQUAD; This spontaneous report was received from a medical assistant referring to a patient of unknown age and gender. The patient's concurrent conditions, pertinent medical history, concomitant medications, drug reactions or allergies were no reported.   On 16-DEC-2021, the patient was vaccinated with temperature excursion involving Measles, Mumps, Rubella and Varicella (Oka-Merck) Virus Vaccine Live (PROQUAD) Lot# U022726 and expiration date 16-JAN-2023 (exact dose, route of administration and frequency were not reported) as prophylaxis.  No additional adverse event (AE) reported (No adverse event).  No PQC reported.
L. arm erythema, warmth and firmness at site of injection - started immediately after vaccination. Advised watchful waiting - patient already on Prednisone and antihistamines - Keflex prescribed for worsening.
received the 1st dose of the vaccine on her right arm and it hurt a little bit; She takes coumadin regularly and measured her coumadin level to be at 1.6 after getting the 1st dose. 2 weeks after, she mentioned that her level was 3 point something which was too high; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP) from medical information team for a Pfizer sponsored program (159558). The reporter is the patient.  A female patient received bnt162b2 (BNT162B2), administered in arm right, administration date 03Mar2021 (Batch/Lot number: unknown) as dose 1, single for covid-19 immunisation. Relevant medical history included: "strokes" (unspecified if ongoing), notes: had 2 bad strokes a few years ago; "heart attack on the left side" (unspecified if ongoing), notes: heart attack on the left side; "chronic pain" (unspecified if ongoing); "bone issues" (unspecified if ongoing); "leukemia in the bone" (unspecified if ongoing); "TIH" (unspecified if ongoing); "thyroid" (unspecified if ongoing). Concomitant medication(s) included: COUMADIN. The following information was reported: PAIN IN EXTREMITY (non-serious), outcome "unknown", described as "received the 1st dose of the vaccine on her right arm and it hurt a little bit"; DRUG LEVEL INCREASED (non-serious), outcome "unknown", described as "She takes coumadin regularly and measured her coumadin level to be at 1.6 after getting the 1st dose. 2 weeks after, she mentioned that her level was 3 point something which was too high". Relevant laboratory tests and procedures are available in the appropriate section.   No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
Pnuemovax 0.5ml injection- injection site redness, skin area is dry and itchy,  Dr notified and will f/u with pt (primary physician)
After vaccination, the Executive Director called to let us know that the family alerted him that the patient previously received their booster dose the month prior.
One month after the second dose of Moderna I checked my irregular heart beat. There really is no treatment. This irregular heartbeat is still ongoing.
This is a spontaneous report from a contactable physician communicated to a Pfizer sales representative. A 16 year old female patient received the first dose of TRUMENBA on an unknown date at single dose for healthy adolescents age 16-23 years old (Immunisation) then went to school. The next day the patient did not feel good, had a fever of 101 degrees. She was starting to feel sick described as she felt hot, tired, and a little down. The patient was out of school the next day and then the third day following the vaccine felt better and went back to school. After the meningococcal group B RLP2086 second dose, she had a slight fever of 101 degrees. She received the vaccine on a Friday and went back to school the following Monday. No other details provided.
This spontaneous report as received from a certified medical assistant (C.M.A.) refers to a patient of unknown age and gender. The patient's medical history, concurrent conditions and concomitant medications were not provided. On 16-FEB-2016, the patient was vaccinated with an improperly stored (temperature: 58 degrees Fahrenheit (F), time frame: 1 hour and 30 minutes; no previous temperature excursion was reported) dose of MMR II lot # L007217, expiration date 03-MAR-2017 (albumin status, dose and route of administration were not specified). No adverse effect was reported. This is one of several reports received from the same reporter. Additional information has been requested.
20 y/o male developed exertional chest pain and dyspnea while performing a physical fitness test.  EKG was normal.  Troponins drastically elevated.  Admitted to Hospital.  Diagnosed with myocardititis after receving smallpox vaccine 10 days prior to onset of symptoms.  Hospitalized for 5 days, discharged in good condition.
fever up to 101 degrees F; headache; 16-year-old in Maryland was given Moderna booster on Friday; pain at the injection site; This spontaneous case was reported by a consumer and describes the occurrence of INJECTION SITE PAIN (pain at the injection site), PYREXIA (fever up to 101 degrees F), HEADACHE (headache) and PRODUCT ADMINISTERED TO PATIENT OF INAPPROPRIATE AGE (16-year-old in Maryland was given Moderna booster on Friday) in a 16-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     Previously administered products included for COVID-19 vaccination: Pfizer Vaccine (First dose) on 17-Apr-2021 and Pfizer Vaccine (Second dose) on 08-May-2021. Past adverse reactions to the above products included No adverse event with Pfizer Vaccine and Pfizer Vaccine.    On 17-Dec-2021, the patient received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) .25 ml. On 17-Dec-2021, the patient experienced INJECTION SITE PAIN (pain at the injection site) and PRODUCT ADMINISTERED TO PATIENT OF INAPPROPRIATE AGE (16-year-old in Maryland was given Moderna booster on Friday). On an unknown date, the patient experienced PYREXIA (fever up to 101 degrees F) and HEADACHE (headache). The patient was treated with IBUPROFEN (ADVIL [IBUPROFEN]) for Adverse event, at a dose of 1 dosage form. On 17-Dec-2021, PRODUCT ADMINISTERED TO PATIENT OF INAPPROPRIATE AGE (16-year-old in Maryland was given Moderna booster on Friday) had resolved. At the time of the report, INJECTION SITE PAIN (pain at the injection site), PYREXIA (fever up to 101 degrees F) and HEADACHE (headache) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On an unknown date, Body temperature: 101 (High) Fever up to 101 degrees F.         The reporter states that, the patient experienced only the common side effects in the 46 hours since the injection. And all the events were mitigated by Advil.  Concomitant medication information was not reported
20MAR91 Neg Anti Hbs p/3 series vax; Expected 90% seroconversion; About 1/3 of employees not immune p/ 1 1/2 yrs post vax; Pt 1st dose 21APR89, 2nd 19MAY89, 3rd 20OCT89 fr lot#'s 1893P & 1802R to receive 4th & 5th vax in MAY & JUN91;
SORES IN MOUTH; This spontaneous report received from a patient concerned a female of unspecified age. The patient's height, and weight were not reported. No past medical history or concurrent conditions were reported. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, batch number: UNKNOWN) dose, start therapy date were not reported for prophylactic vaccination. The batch number was not reported. The Company is unable to perform follow-up to request batch/lot numbers. No concomitant medications were reported. On an unspecified date, the subject experienced sores in mouth. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The outcome of sores in mouth was not reported. This report was non-serious.
possibly has long COVID/symptoms keep mutating and has gotten a lot better and is still not 100%; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A female patient received BNT162b2 (BNT162B2), on 14Jul2022 as dose number unknown (booster), single (Batch/Lot number: unknown) for covid-19 immunisation; coviD-19 vaccine (COVID-19 VACCINE), as dose number unknown, single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported.  The following information was reported: POST-ACUTE COVID-19 SYNDROME (non-serious), outcome "unknown", described as "possibly has long COVID/symptoms keep mutating and has gotten a lot better and is still not 100%". Relevant laboratory tests and procedures are available in the appropriate section.  Additional information: The patient was contemplating getting another Pfizer Booster and has had something for the past 5 months and she believed this is long COVID but no one can diagnose. Her symptoms keep mutating and has gotten a lot better and is still not 100% and she can't get any answers. The last time she got a COVID-19 Vaccine booster was 14Jul2022 and she doesn't know if long haulers get better or worse with a booster and looking for more information.   The information on the batch/lot number for BNT162b2 has been requested and will be submitted if and when received.
pt diagnosed positive for COVID by PCP; pt presents to ED afterwards c/o myalgias x 4 days; BS was greatly elevated in the ED; DKA; admitted to hospital; AHRF secondary to COVID pneumonia; intubated on mechanical ventilation with prone positioning; pt's condition declined and he passed away in the hospital
no ad; Expired vaccine used; This spontaneous case was reported by a pharmacist and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (Expired vaccine used) and NO ADVERSE EVENT (no ad) in an 83-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 042J21A) for COVID-19 prophylaxis.     No Medical History information was reported.   On 04-Mar-2022, the patient received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 04-Mar-2022, the patient experienced EXPIRED PRODUCT ADMINISTERED (Expired vaccine used). On an unknown date, the patient experienced NO ADVERSE EVENT (no ad). At the time of the report, EXPIRED PRODUCT ADMINISTERED (Expired vaccine used) and NO ADVERSE EVENT (no ad) outcome was unknown.      For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter considered NO ADVERSE EVENT (no ad) to be not related. No further causality assessment was provided for EXPIRED PRODUCT ADMINISTERED (Expired vaccine used).    No concomitant medications were reported. Patient received Moderna vaccine beyond the 30 day beyond use date. Beyond use date for lot was 17-Feb-2022 and patient received vaccine on 04-Apr-2022. No treatment medications were reported.   This case was linked to US-MODERNATX, INC.-MOD-2023-704416 (E2B Linked Report).   Most recent FOLLOW-UP information incorporated above includes: On 24-Jan-2023: Live Non Significant follow Up received.; Sender's Comments:  US-MODERNATX, INC.-MOD-2023-704416:Master case
pt devel extreme pain & reduced ROM p/vax;pt reported inability to lift arm more than 20 degrees;also happened last year w/inj & LMD advised pt not to get vax again;
Delayed onset injection site reaction. 2 red circles approx. 2" in diameter in figure 8 pattern on left deltoid (injection site). Minor itching. Ongoing at 48 hours post-identificaction but appears to be resolving.
This case was reported by a consumer via call center representative and described the occurrence of nausea in a 64-year-old male patient who received SHINGRIX for prophylaxis. Previously administered products included SHINGRIX with an associated reaction of pain (1st dose received on 29th March 2018, for tolerance see case US2018171939). On an unknown date, the patient received the 2nd dose of SHINGRIX. On an unknown date, less than a day after receiving SHINGRIX, the patient experienced nausea, fever, urinary frequency, ringing in ears and dizziness. On an unknown date, the outcome of the nausea, fever, urinary frequency, ringing in ears and dizziness were recovered/resolved. It was unknown if the reporter considered the nausea, fever, urinary frequency, ringing in ears and dizziness to be related to SHINGRIX. Additional details were provided as follows: In 2018, the patient received the vaccine within 3 weeks before the time of reporting.
severe headache, pain swelling in my arm, overall malaise and lethargy,  feeling like I can't function
hives along with low grade fever of 38C on bilateral arms, face, and back 2 days after 2nd Hep A vaccine.
DTaP reacted after 12 hours with redness and swelling at site. Prevnar reacted same as above. Child had no fever and appeared alert. Advised cold compress to reduce swelling and Tylenol PRN.
SORE SHOULDER; FATIGUE; This spontaneous report received from a patient concerned a male of unspecified age. The patient's weight, height, and medical history were not reported. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, batch number: Unknown) dose was not reported, administered on 07-APR-2021 to right arm for prophylactic vaccination. The batch number was not reported. The Company is unable to perform follow-up to request batch/lot numbers. No concomitant medications were reported.  On 08-APR-2021, the subject experienced sore shoulder. On 08-APR-2021, the subject experienced fatigue. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The patient was recovering from sore shoulder, and fatigue. This report was non-serious.
during 1st 48hr p/vax pt devel t101 R;pt tx w/Ibuprofen;later devel fine red raised rash;speckeled in appearance on abd & buttocks;
His shoulder has been sore since the injection and hurts to lift his arm.  He has also felt like he has had a cold since the vaccination too.  He is not sure if the arm pain is from the vaccine or pre-existing.
More than 36 days after the first dose without receiving the second dose, finally got the injection on 06May2021; pain in the injection site; This spontaneous case was reported by a consumer and describes the occurrence of INJECTION SITE PAIN (pain in the injection site) and INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (More than 36 days after the first dose without receiving the second dose, finally got the injection on 06May2021) in a 64-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 004C21A. and 038A21A) for COVID-19 vaccination.     No Medical History information was reported.   On 18-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 06-May-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 06-May-2021, the patient experienced INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (More than 36 days after the first dose without receiving the second dose, finally got the injection on 06May2021). In May 2021, the patient experienced INJECTION SITE PAIN (pain in the injection site). At the time of the report, INJECTION SITE PAIN (pain in the injection site) outcome was unknown and INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (More than 36 days after the first dose without receiving the second dose,finally got the injection on 06May2021) had resolved.            no concomitant medications are provided. treatment to the events not reported.   This case was linked to MOD-2021-328736 (Patient Link).
planning to administer PEDV AX HIB to a 73 year old male patient; planning to administer PEDV AX HIB to a 73 year old male patient; no adverse event; This spontaneous report was received from a registered nurse and refers to a 73 year old male patient. The patient's concurrent conditions, medical history and concomitant therapies were not provided.  The reporter was planning to administered haemophilus b conjugate vaccine (meningococcal protein conjugate)(LIQUID PEDVAXHIB) (dose, route, vaccination site were not provided), for prophylaxis to the patient.
Rash about the size of a tennis ball. The area is raised. The raised site is hard underneath. The rash is red and itches.
An hour after the second dose of the COVID vaccine was administered, I began to experience intermittent on the same front of the right leg, Since then the pain has been daily.
administered dose which expired; This case was reported by a other health professional via call center representative and described the occurrence of expired vaccine used in a 17-year-old female patient who received Men B NVS (Bexsero) (batch number Abxa87az, expiry date 31st January 2022) for prophylaxis.   Co-suspect products included meningococcal B recom vaccine + aloh + omv pre-filled syringe device (Bexsero Pre-Filled Syringe Device) injection syringe for prophylaxis.   On 2nd February 2022, the patient received Bexsero and Bexsero Pre-Filled Syringe Device. On 2nd February 2022, unknown after receiving Bexsero and Bexsero Pre-Filled Syringe Device, the patient experienced expired vaccine used. On an unknown date, the outcome of the expired vaccine used was unknown.   This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences.  Additional details were provided as follows: The patient received dose of Bexsero in left deltoid. The medical assistant reported that, the patient received expired dose of Bexsero, which led to expired vaccine used. The reporter did not consent to follow up.
Had travel assess done. Received oral typhoid Rx from downtown pharmacy and started on 2/8/03. On 2/9/03 developed symptoms of gastric distress - burning in esophagus - developed rectal bleeding "from internal hemorrhoid" on 2/13. From 2/15 to 2/19 developed muscle cramps right side up back to neck, localizing in lower back. On 2/20 developed URI with lethargy. 2/26 shaky chills with fever. Seen by PCP on 2/27/03. Watch and wait approach. Symptoms resolved on 3/3/03 without recurrence.
HEADACHE FEVER DIZZINESS IMBALANCE FLAVORED TONGUE HIGH SUGAR
Fever for a month CT Scan found that my Spleen was enlarged  liver enzymes elevated for a month and a half.  Induration about 3 inches long and 2 inches wide red and hot.
Fever, headache, body aches, fatigue: Lasted about 24 hours. Arm rash (appeared one week later lasting for a week).
Information has been received from a registered nurse concerning an elementary school aged child who was vaccinated with a dose of varicella virus vaccine live. On approximately 23-FEB-2006, the patient developed breakthrough chickenpox. Unspecified medical attention was sought. There was no product quality complaint involved. No further information was available. Additional information has been requested.